Medicxi closes third fund on €400m

The vehicle will invest across the full spectrum of healthcare companies from early-stage biotechnology firms to late-stage clinical assets.

The firm has raised two funds since its separation from Index Ventures in 2016: Medicxi Ventures 1 closed on €210m in 2016 and Medicxi Growth 1 closed on c€267m ($300m) in 2017, bringing the total amount raised by Medicxi to almost €900m.

Investors
Novartis and Johnson & Johnson Innovation have acted as cornerstone investors to the new fund and are both returning investors. It also attracted capital from new investors, including hospital foundations and medical institutions.

Investments
Medicxi said it will continue to focus on its "asset-centric" investment model, as well as investing in fully integrated private companies with an underlying platform and/or a pipeline of assets that it believes can deliver licensed pharmaceutical products to satisfy unmet medical needs.

People
Medicxi – Francesco de Rubertis (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• Healthcare
• UK / Ireland
• Venture
• United Kingdom